Back to top
more

Takeda Pharmaceutical Co. (TAK)

(Real Time Quote from BATS)

$14.10 USD

14.10
1,029,590

+0.14 (1.00%)

Updated Nov 4, 2024 02:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?

by Ekta Bagri

ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

TAK or CTLT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TAK vs. CTLT: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tempus Stock Up Following Collaboration Expansion in Oncology R&D

by Zacks Equity Research

TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.

Tracey Ryniec headshot

How Many Stocks Should You Own?

by Tracey Ryniec

Even though there are dozens of great value stocks, that doesn't mean you should own them all.

John Blank headshot

Here is the Year-End FOMC Outlook

by John Blank

After the FOMC cut 50 bps, here is what to expect.

The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America

by Zacks Equity Research

Takeda Pharma, Naspers and Packaging Corp. of America are part of the Zacks top Analyst Blog.

John Blank headshot

The Future Path of U.S. Inflation? Global Week Ahead

by John Blank

U.S. PCE inflation data for August and global business PMI activity surveys for September chart the pressure ahead.

Ekta Bagri headshot

ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?

by Ekta Bagri

ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

TAK vs. STVN: Which Stock Is the Better Value Option?

by Zacks Equity Research

TAK vs. STVN: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ekta Bagri headshot

ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?

by Ekta Bagri

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

by Zacks Equity Research

Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

by Zacks Equity Research

Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.

Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround

by Zacks Equity Research

Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround

by Zacks Equity Research

Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy

by Zacks Equity Research

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

TAK or CTLT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TAK vs. CTLT: Which Stock Is the Better Value Option?

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

New Strong Buy Stocks for April 25th

by Zacks Equity Research

TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.

Best Value Stocks to Buy for April 25th

by Zacks Equity Research

RMNI, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 25, 2024.

Best Income Stocks to Buy for April 25th

by Zacks Equity Research

CIB, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 25, 2024.

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

by Zacks Equity Research

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TAK or STVN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TAK vs. STVN: Which Stock Is the Better Value Option?